Search

Your search keyword '"Ortiz-Maldonado V"' showing total 4 results
Start Over Author "Ortiz-Maldonado V" Topic lymphoma, b-cell
4 results on '"Ortiz-Maldonado V"'

1. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Author

Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, Blázquez A, Cid J, Lozano M, Magnano L, Giné E, Correa JG, Mozas P, Rodríguez-Lobato LG, Rivero A, Montoro-Lorite M, Ayora P, Navarro S, Alserawan L, González-Navarro EA, Castellà M, Sánchez-Castañón M, Cabezón R, Benítez-Ribas D, Setoaín X, Rodríguez S, Brillembourg H, Varea S, Olesti E, Guillén E, Sáez-Peñataro J, de Larrea CF, López-Guillermo A, Pascal M, Urbano-Ispizua Á, Juan M, and Delgado J

Subjects
Humans, Point-of-Care Systems, Immunotherapy, Adoptive adverse effects, Antibodies, Antigens, CD19, T-Lymphocytes, Receptors, Chimeric Antigen, Lymphoma, B-Cell therapy, Lymphoma, Non-Hodgkin therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Varnimcabtagene autoleucel (var-cel) is an academic anti-CD19 chimeric antigen receptor (CAR) product used for the treatment of non-Hodgkin lymphoma (NHL) in the CART19-BE-01 trial. Here we report updated outcomes of patients with NHL treated with var-cel. B-cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty-five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade ≥3) and neurotoxicity in 7% (2% grade ≥3). The objective response rate was 73% at Day +100, and the 3-year duration of response was 56%. The 3-year progression-free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression-free survival. The 3-year incidence of B-cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var-cel was manageable, while B-cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583., (© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

2. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

Author

Mussetti A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, Albo C, Bailen R, Barba P, Benzaquén A, Briones J, Caballero AC, Campos A, Español I, Ferra C, López SG, González Sierra PA, Guerra LM, Hernani R, Iacoboni G, Jiménez-Ubieto A, Kwon M, Corral LL, López-Godino O, Munoz MCM, Martínez-Cibrián N, Gómez JM, Pérez-Ortega L, Ortí G, Ortiz-Maldonado V, Pascual MJ, Perera M, Perez A, Reguera JL, Sanchez JM, Sanz J, Torrent A, Yáñez L, Varela R, Echechipia IC, Caballero D, and Sureda A

Subjects
Humans, Adolescent, Recurrence, Hematopoietic Stem Cell Transplantation methods, Lymphoma, B-Cell therapy
Abstract

Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Español de Trasplante y Terapia Celular (GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse. The analysis included a total of 316 (CART = 215, alloHCT = 101) patients. Median follow-up was 15 and 36 months for the CART and alloHCT cohorts, respectively. In the multivariate analysis, CART was confirmed to be similar to alloHCT for the primary study endpoint (progression-free survival) (hazard ratio [HR] 0.92, CI95%:0.56-1.51, p = 0.75). Furthermore, when the analysis was limited to only patients with chemo-sensitive diseases (complete and partial response) at infusion (CART = 26, alloHCT=93), no differences were reported (progression-free survival at month +18: 65% versus 55%, p = 0.59). However, CART had lower non-relapse mortality (HR 0.34, 95% CI: 0.13-0.85, p = 0.02). Given the lower toxicity and similar survival outcomes, these results suggest the use of CART before alloHCT., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

3. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group.

Author

Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz CP, Metafuni E, Martinez-Lopez J, Dignan FL, Ribera JM, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten MJ, and Mielke S

Subjects
Europe, Humans, Immunotherapy, Adoptive, Leukemia, B-Cell therapy, Lymphoma, B-Cell therapy, Prognosis, Treatment Outcome, COVID-19 complications, Leukemia, B-Cell complications, Leukemia, B-Cell mortality, Lymphoma, B-Cell complications, Lymphoma, B-Cell mortality
Published
2021
Full Text
View/download PDF

4. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Author

Adrian Bloor, Nicolaus Kröger, Gloria Tridello, Alvaro Urbano-Ispizua, Roberta Di Blasi, Joaquin Martinez-Lopez, František Folber, Josep-Maria Ribera, Elisabetta Metafuni, Robin Sanderson, Marie José Kersten, Catherine Thieblemont, Friso Calkoen, Livia Giannoni, Pim G.N.J. Mutsaers, Matthew Collin, Arnon Nagler, Emma Nicholson, Emmanuel Bachy, Fiona L Dignan, Valentín Ortiz-Maldonado, Dolores Caballero, Johan Maertens, Per Ljungman, Pere Barba, Carlos Pinho Vaz, Francis Ayuk, Mi Kwon, Fabio Ciceri, Stephan Mielke, Pierre Sesques, Nina Knelange, Anne M. Spanjaart, Rafael de la Cámara, Institut Català de la Salut, [Spanjaart AM] Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands. [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden. Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. [de La Camara R] Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain. [Tridello G] Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. [Ortiz-Maldonado V, Urbano-Ispizua A] Department of Hematology, Hospital Clínic, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Spanjaart, A. M., Ljungman, P., de La Camara, R., Tridello, G., Ortiz-Maldonado, V., Urbano-Ispizua, A., Barba, P., Kwon, M., Caballero, D., Sesques, P., Bachy, E., Di Blasi, R., Thieblemont, C., Calkoen, F., Mutsaers, P., Maertens, J., Giannoni, L., Nicholson, E., Collin, M., Vaz, C. P., Metafuni, E., Martinez-Lopez, J., Dignan, F. L., Ribera, J. -M., Nagler, A., Folber, F., Sanderson, R., Bloor, A., Ciceri, F., Knelange, N., Ayuk, F., Kroger, N., Kersten, M. J., Mielke, S., Graduate School, Clinical Haematology, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, and Hematology

Subjects
Cancer Research, medicine.medical_specialty, Letter, Lymphoma, B-Cell, Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell [DISEASES], Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B [ENFERMEDADES], Immunotherapy, Adoptive, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], SDG 3 - Good Health and Well-being, Internal medicine, Leukemia, B-Cell, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Humans, Medicine, B cell, COVID-19 (Malaltia) - Complicacions, Haematological cancer, Science & Technology, Hematology, business.industry, Marrow transplantation, COVID-19, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Prognosis, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Lymphoma, Europe, Treatment Outcome, medicine.anatomical_structure, Oncology, Multicenter study, Avaluació de resultats (Assistència sanitària), Infectious diseases, CAR T-cell therapy, Cèl·lules B - Tumors, business, Life Sciences & Biomedicine, Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results